A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement

Trial Profile

A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 12 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 29 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top